ART treatment today can be expected survival time to 70-year-old on the start time of the study ART
Author: Time :2009-2-13 Source:
At present, developed countries start ART guidelines recommend anti-virus treatment time are the beginning of CD4 below 350, for certain special populations, such as high HIV viral load, the merger HCV infection can be administered in advance. But some people think to start treatment as early as minimize damage to HIV on the immune system.
 
The United States and Canada last year, research data concludes that when CD4 dropped to 350 in the ART than before the start down to 350 after the start, 70 percent lower risk of death, but the researchers did not say if the CD4 high to 500 when they will be any results.
 
In Canada, held the 16th anti-virus and anti-opportunistic infections to display the General Assembly 2 for this study, but the conclusions of two studies conflict with each other.
 
North American research in CD4 less than 500 to start treatment at higher than 500 when they increase the risk of death 60%.
 
Another study is co-operation in Europe and North America to observe the data and found no higher than 400 after the start CD4 treatment has any benefit. Found in CD4 between 350-400 obvious benefits to start ART, but in between the 450-550 did not activate or death to reduce the risk of AIDS.
 
The General Assembly noted that the lack of strict comparability of the two studies. Before a risk of death are observed, the latter observation are AIDS and the risk of death. Two studies do not have indications for non-AIDS diseases were observed, and these are early promoter of the most worried about the risks of ART, as well as to prevent these side effects are more worthy of economic input.



http://www.aidsmap.com/en/news/44645131-770C-4D41-AA18-7E2E4116D4E3.asp
ART treatment today can be expected survival time to 70-year-old
Author: China's AIDS treatment information network time :2009-1-29 Source: China AIDS Treatment Information Network
Well-known magazine "Lancet" on the article, researchers from 14 large-scale international clinical points, including Canada, Europe and the United States. Observed a total of 43,000 patients with mortality and prognostic factors. ART start time is divided into 1996-1999,2000-2002,2002-2005 years.
 
Clinical study data show that the success of ART treatment can extend survival to 60 years of age: the success of ART treatment, if it is the beginning of 20-year-old, can live to 63 years old, if it is the beginning of 35-year-old, can live to 67 years. If the above are in the CD4 200 started treatment, 20-year-old can live to 70 years old, 35-year-old can live to 72 years.
 
The study also shows that with improved treatment, ART expected gradually to extend the survival period :1996-1999 period is expected to survive 43 years to 2002-2005, are near 70 years.
 
Intravenous drug users in a shorter survival period of 20 years. Low baseline CD4 is also shortened survival factor. CD4 in 500 risk of death when the treatment of HIV can be ignored. Women overall than men.
 
In spite of this, found HIV-positive individuals than HIV-negative short survival time for 10 years. Non-HIV related complications.